Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05516758 · ClinicalTrials.gov registry record · Phase 2
A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 491
- Enrollment target
NCT05516758 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 491 participants.
The verdict
NCT05516758, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 491 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.
Interventions
- DRUG Placebo
- DRUG Peresolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2025-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05516758
The ClinicalTrials.gov registry entry for NCT05516758 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 491 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05516758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05516758 about?
NCT05516758 is a clinical study titled "A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis". The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoid arthritis.
What is the current status of trial NCT05516758?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 491 participants. The study started on 2022-08-31. Estimated completion is 2025-01-17.
What interventions are being tested in trial NCT05516758?
The interventions under investigation include: Placebo (DRUG), Peresolimab (DRUG).
Who is sponsoring clinical trial NCT05516758?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.